medication | CARLAT PUBLISHING

Does Pioglitazone Lead to Reduced Alcohol Use?

July 1, 2022

Deepti Anbarasan, MD. and Nicholas Apping, MD

Nicholas Apping, MD, and Deepti Anbarasan.

MD. Dr. Apping and Dr. Anbarasan, authors for this educational activity, have no relevant financial relationship(s) with ineligible companies to disclose.

The hunt continues for effective medications for alcohol use disorder. Researchers here investigated the potential utility pioglitazone, a medication commonly used for diabetes management.

Medications for Alcohol Use Disorder: An Overview

March 1, 2022

Mikveh Warshaw, NP.

Mikveh Warshaw, NP. Psychiatric mental health nurse practitioner, Community Health Center Inc. and faculty member of Center for Key Populations (CKP) Program, Middletown, CT. Ms. Warshaw has disclosed no relevant financial or other interests in any commercial companies pertaining to this educational activity.

There are three FDA approved medications for alcohol use disorder (AUD) and many others that have been tested. Here, we summarize the evidence behind the various medications for alcohol use disorder and highlight clinical scenarios in which each should be considered.

CLINICAL UPDATE

Prescribing to Children of Divorce

March 12, 2021

Anthony Charuvastra, MD.

Anthony Charuvastra, MD. Adjunct Assistant Professor, NYU Langone Medical Center Department of Child and Adolescent Psychiatry. Dr. Charuvastra has disclosed that he has no relevant financial or other interests in any commercial companies pertaining to this educational activity.

What is the best approach to effective clinical care with families that are separated or divorced? This article covers the complexities, the legalities, and an expectation of collaboration that can help us to help children to receive good mental health care despite the inevitable differences between parents in these situations.

Buspirone: Still Effective After All These Years?

February 3, 2021

Eugene Rubin, MD.

Eugene Rubin, MD. Psychiatrist in private practice, Bingham Farms, MI. Dr. Rubin has disclosed that he has no relevant financial or other interests in any commercial companies pertaining to this educational activity.

Buspirone (Buspar) is approved for generalized anxiety disorder, but its efficacy there is often questioned. Here we find out how it stacks up against the benzos and SSRIs, and explore its off-label potential in depression, sexual dysfunction, alcoholism, traumatic brain injury, and premenstrual dysphoric disorder.

CLINICAL UPDATE

How to Use Lamotrigine

January 1, 2021

Chris Aiken, MD.

Chris Aiken, MD. Editor-in-Chief of TCPR. Practicing psychiatrist, Winston-Salem, NC. Dr. Aiken has disclosed that he has no relevant financial or other interests in any commercial companies pertaining to this educational activity.

Lamotrigine is approved for the prevention of bipolar episodes, but Dr. Aiken explains why it may also treat active bipolar depression. This mood stabilizer is among the most tolerable in its class, and has additional benefits in OCD, borderline personality disorder, and depersonalization disorder.

EXPERT Q&A

Alternative Therapies for SUDs

December 10, 2020

Steven Novella, MD

Steven Novella, MD
Assistant Professor of Neurology, Yale School of Medicine. Dr. Novella has disclosed that he has no relevant financial or other interests in any commercial companies pertaining to this educational activity.

Not all alternative therapies are created equal. In this interview with Dr. Steven Novella, we discuss the prevalence of alternative therapies among patients with substance use disorders (SUDs) as well as the state of evidence for (or against) commonly utilized forms of complementary and alternative treatments for SUDs.

“What About the Implant, Doc?” Appraising Various Formulations of Buprenorphine

August 6, 2020

Edmund S. Higgins, MD.

Edmund S. Higgins, MD. Clinical Associate Professor of Psychiatry and Family Medicine, MUSC, Charleston, SC. Dr. Higgins has disclosed that he has no relevant financial or other interests in any commercial companies pertaining to this educational activity.

Buprenorphine can be administered via intravenous, transdermal, sublingual, buccal, and implanted formulations. We appraise the evidence for various formulations and suggest certain populations for which certain formulations may be a better choice.

Updated Guidelines for Treating Opioid Use Disorder

August 6, 2020

Rehan Aziz, MD.

Rehan Aziz, MD. Associate Professor of Psychiatry and Neurology, Rutgers Robert Wood Johnson Medical School. Dr. Aziz has disclosed that he has no relevant financial or other interests in any commercial companies pertaining to this educational activity

The American Society of Addiction Medicine released updated guidelines for the management of opioid use disorder (OUD) in March, 2020. They focus on expanding access to methadone and buprenorphine. Additionally, detailed guidance is given for perioperative management of OUD and pain management in patients with OUD.

EXPERT Q&A

Reduced Life Expectancy in ADHD

February 11, 2020

Russell Barkley, PhD

Russell Barkley, PhD
Clinical Professor of Psychiatry at The Virginia Commonwealth University Medical Center, Department of Psychiatry and the Virginia Treatment Center for Children Dr. Barkley has disclosed that he has no relevant financial or other interests in any commercial companies pertaining to this educational activity.

Russell Barkley, PhD, discusses the enormity of the health consequences and early mortality associated with ADHD. The range and likely mechanism of long-term effects of ADHD are discussed, and we examine the role of assertive treatment in childhood and adolescence.

Can Stimulants Prevent Crime?

February 11, 2020

Thomas Jordan, MD.

Thomas Jordan, MD. Dr. Jordan has disclosed that he has no relevant financial or other interests in any commercial companies pertaining to this educational activity.

The link between ADHD and antisocial behavior leading to arrests and incarcerations is often not clear: is the ADHD causing the behaviors or other related factors? We examine the results of a population-based study to give us insight into whether treating ADHD with stimulant medication has an effect on the risk of criminal behavior.